Bernhard Heinrich
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bernhard Heinrich has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Christian Engelbrecht
Medical Affairs, Eisai GmbH, 60549 Frankfurt, Germany
2 shared publications - Christian Jackisch
Kliniken Essen Mitte gGmbH - KEM- Essen, Germany
2 shared publications - Cosima Zemlin
Department of Gynecology, Obstetrics & Reproductive Medicine, Saarland University Medical Center, 66421 Homburg, Germany
2 shared publications - Dorothea Fischer
Department of Obstetrics and Gynaecology, Ernst von Bergmann Clinic, 14467 Potsdam, Germany
2 shared publications - Eva-Maria Grischke
Department of Obstetrics and Gynecology, University of Tubingen, Tubingen, Germany
2 shared publications - Harald Müller Huesmann
Department of Internal Medicine, Hematology and Oncology, St Josef Brothers Hospital, 33098 Paderborn, Germany
2 shared publications
Latest Publications
- Open Access
Eribulin-Induced Peripheral Neuropathy in Locally Advanced or Metastatic Breast Cancer: Final Analysis of the Prospective Cohort IRENE Study
Eribulin is a preferred treatment for patients with advanced breast cancer (BC) following anthracyclines and taxanes. The final analysis of the IRENE study assessed the incidence and resolution of eribulin-induced peripheral neuropathy (EIPN), along with safety and quality of life (QoL), in patients with advanced/metastatic BC. IRENE was an observational, single-arm, prospective, multicenter cohort study. Patients aged ≥18 years with locally advanced/metastatic BC that progressed after 1–3 prior chemotherapeutic regimens received eribulin and were monitored for new-onset or worsening EIPN. Secondary endpoints included time to disease progression, safety, and health-related QoL. In total, 108 (32.2%) out of 335 patients experienced EIPN; 18 (5.4%) experienced grade ≥3 EIPN. Median time to EIPN resolution (EIPN ended or returned to baseline) was 78.7 weeks (95% CI 77.1—not estimable). Median time to disease progression was 4.5 months (95% CI 3.9–5.5). Treatment-emergent adverse events (TEAEs) occurred in 322 (96.1%) patients; serious TEAEs occurred in 185 (55.2%) patients. Incidence and resolution rates of EIPN were comparable with existing evidence from previous trials. TEAEs were consistent with the established eribulin safety profile, with no new safety signals. Eribulin treatment did not appear to affect QoL, as measured by EQ-5D-3L and EQ-VAS, or patient-reported neuropathy symptoms, as measured by the PNQ.
Open AccessEribulin-Induced Peripheral Neuropathy in Locally Advanced or Metastatic Breast Cancer: Final Analysis of the Prospective Cohort IRENE Study
Eribulin is a preferred treatment for patients with advanced breast cancer (BC) following anthracyclines and taxanes. The final analysis of the IRENE study assessed the incidence and resolution of eribulin-induced peripheral neuropathy (EIPN), along with safety and quality of life (QoL), in patients with advanced/metastatic BC. IRENE was an observational, single-arm, prospective, multicenter cohort study. Patients aged ≥18 years with locally advanced/metastatic BC that progressed after 1–3 prior chemotherapeutic regimens received eribulin and were monitored for new-onset or worsening EIPN. Secondary endpoints included time to disease progression, safety, and health-related QoL. In total, 108 (32.2%) out of 335 patients experienced EIPN; 18 (5.4%) experienced grade ≥3 EIPN. Median time to EIPN resolution (EIPN ended or returned to baseline) was 78.7 weeks (95% CI 77.1—not estimable). Median time to disease progression was 4.5 months (95% CI 3.9–5.5). Treatment-emergent adverse events (TEAEs) occurred in 322 (96.1%) patients; serious TEAEs occurred in 185 (55.2%) patients. Incidence and resolution rates of EIPN were comparable with existing evidence from previous trials. TEAEs were consistent with the established eribulin safety profile, with no new safety signals. Eribulin treatment did not appear to affect QoL, as measured by EQ-5D-3L and EQ-VAS, or patient-reported neuropathy symptoms, as measured by the PNQ.
- Open Access
- 29 November 2024
- Published by MDPI AG in Preprints.org
Eribulin-Induced Peripheral Neuropathy in Locally Advanced or Metastatic Breast Cancer: Final Analysis of the Prospective Cohort IRENE Study
Eribulin is a preferred treatment for patients with advanced breast cancer (BC) following anthracyclines and taxanes. The final analysis of the IRENE study assessed the incidence and resolution of eribulin-induced peripheral neuropathy (EIPN), along with safety and quality of life (QoL), in patients with advanced/metastatic BC. IRENE was an observational, single-arm, prospective, multicenter, cohort study. Patients aged ≥18 years with locally advanced/metastatic BC that progressed after 1-3 prior chemotherapeutic regimens received eribulin and were monitored for new-onset or worsening EIPN. Secondary endpoints included time to disease progression, safety, and health-related QoL. 108 (32.2%) Of 335 patients experienced EIPN; 18 (5.4%) experienced grade ≥3 EIPN. Median time to EIPN resolution (EIPN ended or returned to baseline) was 78.7 weeks (95% CI 77.1-not estimable). Median time to disease progression was 4.5 months (95% CI 3.9-5.5). Treatment-emergent adverse events (TEAEs) occurred in 322 (96.1%) patients; serious TEAEs occurred in 185 (55.2%) patients. Incidence and resolution rates of EIPN were comparable with existing evidence from previous trials. TEAEs were consistent with the established eribulin safety profile, with no new safety signals. Eribulin treatment did not appear to affect QoL, as measured by EQ-5D-3L and EQ-VAS, or patient-reported neuropathy symptoms, as measured by the PNQ.
- 29 November 2024
- Published by MDPI AG in Preprints.org
Open AccessEribulin-Induced Peripheral Neuropathy in Locally Advanced or Metastatic Breast Cancer: Final Analysis of the Prospective Cohort IRENE Study
Eribulin is a preferred treatment for patients with advanced breast cancer (BC) following anthracyclines and taxanes. The final analysis of the IRENE study assessed the incidence and resolution of eribulin-induced peripheral neuropathy (EIPN), along with safety and quality of life (QoL), in patients with advanced/metastatic BC. IRENE was an observational, single-arm, prospective, multicenter, cohort study. Patients aged ≥18 years with locally advanced/metastatic BC that progressed after 1-3 prior chemotherapeutic regimens received eribulin and were monitored for new-onset or worsening EIPN. Secondary endpoints included time to disease progression, safety, and health-related QoL. 108 (32.2%) Of 335 patients experienced EIPN; 18 (5.4%) experienced grade ≥3 EIPN. Median time to EIPN resolution (EIPN ended or returned to baseline) was 78.7 weeks (95% CI 77.1-not estimable). Median time to disease progression was 4.5 months (95% CI 3.9-5.5). Treatment-emergent adverse events (TEAEs) occurred in 322 (96.1%) patients; serious TEAEs occurred in 185 (55.2%) patients. Incidence and resolution rates of EIPN were comparable with existing evidence from previous trials. TEAEs were consistent with the established eribulin safety profile, with no new safety signals. Eribulin treatment did not appear to affect QoL, as measured by EQ-5D-3L and EQ-VAS, or patient-reported neuropathy symptoms, as measured by the PNQ.
- 10 June 2021
- Published by Springer Nature in MMW - Fortschritte der Medizin
- Vol. 163 (11) , 5
Familiäre Tumorerkrankung: Erkennen ist Schutz
- 10 June 2021
- Published by Springer Nature in MMW - Fortschritte der Medizin
- Vol. 163 (11) , 5
Familiäre Tumorerkrankung: Erkennen ist Schutz
- 29 April 2021
- Published by Springer Nature in MMW - Fortschritte der Medizin
- Vol. 163 (8) , 66-67
Leukozytose
- 29 April 2021
- Published by Springer Nature in MMW - Fortschritte der Medizin
- Vol. 163 (8) , 66-67
Leukozytose
- 17 December 2020
- Published by Springer Nature in MMW - Fortschritte der Medizin
- Vol. 162 (21-22) , 5
Onkologie im Wandel
- 17 December 2020
- Published by Springer Nature in MMW - Fortschritte der Medizin
- Vol. 162 (21-22) , 5
Onkologie im Wandel
- 19 August 2015
- Published by Springer Nature in MMW - Fortschritte der Medizin
- Vol. 157 (14) , 39-44
Chemotherapie: besser als ihr Ruf
- 19 August 2015
- Published by Springer Nature in MMW - Fortschritte der Medizin
- Vol. 157 (14) , 39-44
Chemotherapie: besser als ihr Ruf
- 14 May 2015
- Published by Springer Nature in MMW - Fortschritte der Medizin
- Vol. 157 (9) , 41-45
Nicht nur Warzen und Zervixkarzinom
- 14 May 2015
- Published by Springer Nature in MMW - Fortschritte der Medizin
- Vol. 157 (9) , 41-45
Nicht nur Warzen und Zervixkarzinom
- 4 December 2008
- Vol. 150, 37-8, 40
[EGFR (epidermal growth factor receptor) inhibitor-associated skin disorders in tumor therapy].
- 4 December 2008
- Vol. 150, 37-8, 40
[EGFR (epidermal growth factor receptor) inhibitor-associated skin disorders in tumor therapy].
- 1 January 2008
- Published by Springer Nature in MMW - Fortschritte der Medizin
- Vol. 150 (1-2) , 46-50
Kardinalsymptom Fieber
- 1 January 2008
- Published by Springer Nature in MMW - Fortschritte der Medizin
- Vol. 150 (1-2) , 46-50
Kardinalsymptom Fieber
- 30 September 2004
- Vol. 146 (40) , 30-2
[Medical treatment of cancer in the elderly].
Paralleling increasing life expectancy, the number of cases of cancer in our population is also on the increase. The question as to whether chemotherapy for the treatment of a tumor in the elderly is appropriate or not, and if so what doses are required, depends in particular on the potentially increased toxicity of the drug in the old patient. The consequence is that alternative substances may have to be sought. When planning treatment, however, additional factors have to be taken into account, such as the possibility of differences in the physiology of the tumor in the elderly, the general state of health of the patient, the presence of concomitant diseases, possible interactions with other medications, and the patient's social environment.
- 30 September 2004
- Vol. 146 (40) , 30-2
[Medical treatment of cancer in the elderly].
Paralleling increasing life expectancy, the number of cases of cancer in our population is also on the increase. The question as to whether chemotherapy for the treatment of a tumor in the elderly is appropriate or not, and if so what doses are required, depends in particular on the potentially increased toxicity of the drug in the old patient. The consequence is that alternative substances may have to be sought. When planning treatment, however, additional factors have to be taken into account, such as the possibility of differences in the physiology of the tumor in the elderly, the general state of health of the patient, the presence of concomitant diseases, possible interactions with other medications, and the patient's social environment.